InB-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis -: art. no. 105

被引:22
作者
Sturm, I
Bosanquet, AG
Hummel, M
Dörken, B
Daniel, PT
机构
[1] Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13353 Berlin, Germany
[2] Humboldt Univ, Univ Med Ctr Charite, Dept Hematol & Oncol, D-13353 Berlin, Germany
[3] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany
[4] Royal United Hosp, Bath BA1 3NG, Avon, England
[5] Humboldt Univ, Univ Med Ctr Charite, Inst Pathol, D-12300 Berlin, Germany
关键词
D O I
10.1186/1471-2407-5-105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A common sequence polymorphism at codon 72 of the p53 gene encoding either arginine or proline was recently shown to be functionally relevant for apoptosis induction in vitro. In B-type chronic lymphocytic leukemia (B-CLL), p53 gene mutations occur in a subset of patients and are associated with impaired survival and drug resistance. Here, we address the functional relevance of the codon 72 single nucleotide ( SNP) polymorphism for cell death sensitivity following exposure to clinically employed cytotoxic drugs and gamma-irradiation. Methods: 138 B-CLL samples were analysed by SSCP-PCR and sequencing for single nucleotide polymorphism at codon 72 of the p53 gene. The in vitro cytotoxicity assay (DiSC-assay) was performed with 7 drugs ( chlorambucil, mafosfamide, fludarabine phosphate, methylprednisolone, doxorubicin, vincristine) or gamma-irradiation. Results: Of the138 B-CLL samples, 9 samples were homozygous for proline (Pro/Pro), 78 samples homozygous for arginine ( Arg/Arg), and 49 samples heterozygous (Arg/Pro). No differences were found for patient survival and cell death triggered by 7 cytotoxic drugs or gamma-irradiation. Conclusion: These data indicate that polymorphic variants of p53 codon 72 are not clinically relevant for apoptosis induction or patient survival in B-CLL.
引用
收藏
页数:5
相关论文
共 29 条
[1]   The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells [J].
Baptiste, N ;
Friedlander, P ;
Chen, XB ;
Prives, C .
ONCOGENE, 2002, 21 (01) :9-21
[2]  
Bergamaschi G, 2004, HAEMATOLOGICA, V89, P868
[3]  
Boltze C, 2002, INT J ONCOL, V21, P1151
[4]  
Bonafé M, 2003, CLIN CANCER RES, V9, P4860
[5]   P53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes [J].
Bonafè, M ;
Salvioli, S ;
Barbi, C ;
Mishto, M ;
Trapassi, C ;
Gemelli, C ;
Storci, G ;
Olivieri, F ;
Monti, D ;
Franceschi, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (04) :539-541
[6]   Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined disc assay methodology [J].
Bosanquet, AG ;
Bell, PB .
LEUKEMIA RESEARCH, 1996, 20 (02) :143-&
[7]  
Bosanquet AG, 1996, BLOOD, V87, P1962
[8]   Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia [J].
Bosanquet, AG ;
Bosanquet, MI .
LEUKEMIA, 2000, 14 (04) :712-715
[9]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[10]   A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA [J].
Gemignani, F ;
Moreno, V ;
Landi, S ;
Moullan, N ;
Chabrier, A ;
Gutiérrez-Enríquez, S ;
Hall, J ;
Guino, E ;
Peinado, MA ;
Capella, G ;
Canzian, F .
ONCOGENE, 2004, 23 (10) :1954-1956